Trulieve Cannabis Corp.(TRLV)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Limited institutional coverage
Quality rankings require at least 50 unique 13-F institutional holders to ensure peer comparisons are meaningful. Only 0 institutional filers currently hold this stock.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
TRLV Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Trulieve Cannabis Corp. (TRLV), a Healthcare sector company. TRLV is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least 50 unique 13-f institutional holders to ensure peer comparisons are meaningful. only 0 institutional filers currently hold this stock. Based on the latest XBRL financial filings (Q1 2026), Trulieve Cannabis Corp. reports quarterly revenue of $286.8M, net income of $2.3M, an operating margin of 12.5%. TRLV trades on the NYSE exchange and files with the SEC under CIK 1754195. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TRLV daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Trulieve Cannabis Corp. directly from SEC EDGAR.
Revenue
Q1 2026
$286.8M
Net Income
Q1 2026
$2.3M
Free Cash Flow
Q1 2026
$42.2M
Operating Margin
Q1 2026
12.5%
ROIC
Q1 2026
2.7%
D/E Ratio
Q1 2026
0.17
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
-0.4% YoYNet Income
+25.0% YoYOperating Income
+46.8% YoYEPS (Diluted)
+26.6% YoYTotal Assets
-6.1% YoYTotal Debt
-62.5% YoYOp. Cash Flow
+0.5% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $1.18B -0.4% | $1.19B +5.1% | $1.13B -7.3% | $1.22B +29.8% | $938.4M +79.9% | $521.5M |
| Net Income | $-116.4M +25.0% | $-155.1M +70.6% | $-526.8M -108.4% | $-252.7M -1548.7% | $17.4M -72.3% | $63.0M |
| Operating Income | $143.5M +46.8% | $97.8M +144.1% | $-221.6M -541.8% | $50.2M -75.4% | $204.1M -6.5% | $218.3M |
| EPS (Diluted) | $-0.58 +26.6% | $-0.79 +65.4% | $-2.28 -140.0% | $-0.95 -891.7% | $0.12 -77.4% | $0.53 |
| Total Assets | $2.70B -6.1% | $2.87B +5.2% | $2.73B -19.7% | $3.40B -0.3% | $3.41B +321.3% | $809.8M |
| Total Debt | $136.7M -62.5% | $364.8M +0.4% | $363.2M -32.9% | $541.7M +17.0% | $462.9M | — |
| Operating Cash Flow | $272.8M +0.5% | $271.5M +34.5% | $201.8M +773.9% | $23.1M +79.1% | $12.9M -87.1% | $99.6M |
AI Insight: TRLV Financial Trends
Debt cut by 63% to $196M in Q1 2026, but revenue remains stuck near $287–302M range with operating income volatile.
• Total debt plummeted from $366M in Q3 2025 to $137M in Q4 2025, then rose to $196M in Q1 2026 — largest deleveraging in dataset.
• Operating cash flow averaged $66M over last four quarters; most recent $56M aligns with mid-range performance.
• Revenue flat-lined: Q2 2024 $303M vs. Q1 2026 $287M, down 5% over nine quarters with no sustained growth.
⚠ Operating income swings wildly: Q2 2025 $53M, Q4 2025 $15M, Q1 2026 $36M — consistency issue masks true operational power.
⚠ Debt rebound from $137M to $196M in one quarter signals capital raise or refinancing — monitor sustainability of deleveraging.
AI Insight: TRLV Ratio Trends
Operating margin recovery masks volatile profitability: OpMargin rebounded to 12.5% in Q1 2026, but ROIC remains 1.6pp below TTM despite sequential deterioration.
• OpMargin fell to 0.2% in Q3 2024, then recovered to 17.4% in Q2 2025—strongest quarter—before settling at 12.5% in Q1 2026.
• ROIC collapsed to 0.7% in Q3 2024 and 1.4% in Q4 2024, then rebounded to 73.0% in Q1 2026 TTM, showing operational turnaround.
• Net profit margin deteriorated sharply: -4.0% in Q2 2024 worsened to -21.7% in Q3 2024, indicating severe profitability stress mid-2024.
⚠ OpMargin declined 1.9pp sequentially from Q4 2025 (5.2%) to Q1 2026 (12.5%), reversing Q2 2025's 17.4% peak.
⚠ ROIC volatility persists: dropped from 57.6% (Q2 2025) to 44.8% (Q4 2025)—largest single-quarter decline—suggesting uneven operational execution.
Get alerted when TRLV's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Trulieve Cannabis Corp. including:
More Healthcare Companies
View all Healthcare →Put TRLV on your watchlist
Track score changes the day Trulieve Cannabis Corp. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is TRLV a good stock to buy?
13F Pro's AI-powered analysis of Trulieve Cannabis Corp. (TRLV) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TRLV are available on the TRLV stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own TRLV?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TRLV. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Trulieve Cannabis Corp.'s investment landscape.